Alvotech makes deal with Fuji Pharma for biosimilars in Japan

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

Alvotech makes deal with Fuji Pharma for biosimilars in Japan

Home/Pharma News | Posted 30/11/2018 0 Post your comment

Iceland-based biopharmaceutical company Alvotech and Japan-based Fuji Pharma announced on 19 November 2018 that they had entered into an exclusive partnership for biosimilars in Japan.

Under the terms of the partnership, Alvotech, a sister company of US generics company Alvogen, will develop and supply biosimilars from its current pipeline. Fuji Pharma will then be responsible for registering and selling the biosimilars in Japan. Alvotech says that its biosimilar portfolio includes products for the treatment of oncology, ophthalmology and autoimmune diseases that generated over US$32 billion in global sales in 2017.

According to Fuji Pharma’s President and CEO Eiji Takamasa, ‘Fuji Pharma’s strong market reach in Japan, complemented with Alvotech’s futuristic portfolio of the expected first‐to‐launch biosimilar products, will provide the critical synergies for the success of this partnership’. While Rasmus Rojkjaer, Alvotech’s Chief Executive Officer believes that ‘combining Alvotech’s significant manufacturing capacity and high value biosimilars portfolio with Fuji Pharma’s deep market experience’ will make the companies ‘leaders in Japan’s rapidly growing biosimilars market’, which is forecast to have a compound annual growth rate (CAGR) of as much as 35% over the next years.

This is not the first collaboration Alvotech has entered into. In March 2014, the company made a deal with US-based bio-process management company Finesse Solutions for bio-manufacturing [1]. Then in September 2018, Alvotech entered into a joint venture with China-based Changchun High & New Technology Industries Group (CCHN), which will enable Alvotech to develop, manufacture and commercialize its biosimilar portfolio in China [2].

Related article
Alvotech invests US$250 million in biosimilars

References
1. GaBI Online - Generics and Biosimilars Initiative. Alvotech and Finesse enter into biosimilars collaboration [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Nov 30]. Available from: www.gabionline.net/Biosimilars/News/Alvotech-and-Finesse-enter-into-biosimilars-collaboration
2. GaBI Online - Generics and Biosimilars Initiative. Biosimilar partnerships for Alvotech and Pall Biotech [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Nov 30]. Available from: www.gabionline.net/Pharma-News/Biosimilar-partnerships-for-Alvotech-and-Pall-Biotech

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: Fuji Pharma